BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Sorafenib (Nexavar, BAY43-9006)
Drug: Eribulin

First Posted Date: 2012-04-26

Last Posted Date: 2015-10-27

Lead Sponsor: Bayer

Target Recruit Count: 40

Registration Number: NCT01585870

Duration of Treatment With Tyrosine Kinase Inhibitors in the Treatment of Metastatic Renal Cell Carcinoma

Completed

Conditions: Renal Cell Carcinoma

Interventions: Other: No intervention

First Posted Date: 2012-04-26

Last Posted Date: 2016-10-19

Lead Sponsor: Bayer

Target Recruit Count: 151

Registration Number: NCT01585974

Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy

Phase 3

Completed

Conditions: Colorectal Neoplasms

Interventions: Drug: Regorafenib (BAY73-4506)
Drug: Placebo

First Posted Date: 2012-04-25

Last Posted Date: 2016-02-08

Lead Sponsor: Bayer

Target Recruit Count: 204

Registration Number: NCT01584830

Xarelto [SPAF] Post-marketing Surveillance in Japan

Completed

Conditions: Brain Ischemia

Interventions: Drug: Rivaroxaban(Xarelto, BAY59-7939)

First Posted Date: 2012-04-23

Last Posted Date: 2023-07-24

Lead Sponsor: Bayer

Target Recruit Count: 11310

Registration Number: NCT01582737

A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A

Phase 2

Completed

Conditions: Hemophilia A

Interventions: Biological: BAY94-9027

First Posted Date: 2012-04-19

Last Posted Date: 2023-11-07

Lead Sponsor: Bayer

Target Recruit Count: 145

Registration Number: NCT01580293

Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)

Phase 1

Terminated

Conditions: Small Cell Lung Carcinoma

Interventions: Drug: Roniciclib (BAY1000394)
Drug: Etoposide
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2012-04-09

Last Posted Date: 2021-04-08

Lead Sponsor: Bayer

Target Recruit Count: 43

Registration Number: NCT01573338

Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients

Phase 1

Completed

Conditions: Prostatic Neoplasms

Interventions: Drug: Radium-223 dichloride (Xofigo, BAY88-8223)

First Posted Date: 2012-03-29

Last Posted Date: 2016-10-17

Lead Sponsor: Bayer

Target Recruit Count: 19

Registration Number: NCT01565746

A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ3939 in Patients With Bacterial Pneumonia

Phase 3

Completed

Conditions: Pneumonia

Interventions: Drug: Ciprofloxacin (Cipro, BAYQ3939)

First Posted Date: 2012-03-23

Last Posted Date: 2015-04-27

Lead Sponsor: Bayer

Target Recruit Count: 44

Registration Number: NCT01561794

Nexavar Dosing in Renal Cancer Patients in "Real-life" Setting

Completed

Conditions: Carcinoma, Renal Cell

Interventions: Drug: Sorafenib (Nexavar, BAY43-9006)

First Posted Date: 2012-03-19

Last Posted Date: 2017-03-28

Lead Sponsor: Bayer

Target Recruit Count: 205

Registration Number: NCT01557127

A 3-fold Crossover Bioequivalence Study Between Glucobay ODT (Orally Disintegrating Tablet) 100 mg and Glucobay Standard Tablet 100 mg

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Acarbose (Glucobay, BAYG5421)
Drug: Acarbose (Glucobay ODT, BAYG5421)

First Posted Date: 2012-03-15

Last Posted Date: 2013-06-14

Lead Sponsor: Bayer

Target Recruit Count: 34

Registration Number: NCT01554631

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy